Overview

This trial is active, not recruiting.

Conditions x-linked retinoschisis, xlrs
Treatment dorzolamide 2% tid or brinzolamide 1% tid
Sponsor Applied Genetic Technologies Corp
Collaborator Foundation Fighting Blindness
Start date March 2012
End date December 2016
Trial size 55 participants
Trial identifier NCT02331173, XLRS-001

Summary

The purpose of this study is to evaluate subjects with X-linked retinoschisis in a clinical setting to collect data on disease progression.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
All subjects enrolled in this study will be seen every 6 months following the screening visit. During the 3 main study visits, a series of tests will be performed to assess visual function. Some of these tests are part of routine care that patients would receive on an annual basis regardless of study participation. Other tests are being performed to determine if they are effective at monitoring disease progression in this population. For each of the 3 main study visits, testing may be spread over multiple days to ensure completion of all tests.
Subjects with maculoschisis may be offered topical treatment with CAIs. These subjects will be asked to visit the study site at 1 month and 3 months after starting topical treatment. During these additional visits, subjects will undergo a dilated eye exam, BCVA, and SD-OCT imaging to assess efficacy of treatment (i.e. reduction of maculoschisis).
dorzolamide 2% tid or brinzolamide 1% tid
Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows: Topical dorzolamide 2% three times per day Topical brinzolamide 1% three times per day

Primary Outcomes

Measure
Disease progression in subjects with XLRS
time frame: Every 6 months for 18 months

Secondary Outcomes

Measure
Disease progression using microperimetry, a non-standard of care visual function test
time frame: Every 6 months for 18 months
Disease progression using electroretinograms (ERGs), a non-standard of care visual function test
time frame: Every 6 months for 18 months
Disease progression using the reading speed test, a non-standard of care visual function test
time frame: Every 6 months for 18 months
Disease progression using the contrast sensitivity test, a non-standard of care visual function test
time frame: Every 6 months for 18 months
Disease progression using a quality of life questionnaire
time frame: Every 6 months for 18 months
Change in maculoschisis while receiving carbonic anhydrase inhibitors
time frame: All study visits, Months 1, 3, 6, 12, and 18
Change in visual function while receiving carbonic anhydrase inhibitors
time frame: All study visits, Months 1, 3, 6, 12, and 18

Eligibility Criteria

Male participants at least 7 years old.

Inclusion Criteria: Main Study: - Clinical diagnosis consistent with XLRS - Documented disease causing RS1 mutation - 7 years of age or older - Able to provide informed consent/assent - Male CAI sub-study: • Presence of maculoschisis Exclusion Criteria: Main Study: • Other eye diseases that might affect the results (e.g. history of retinal detachment, glaucoma, cataracts that prohibit imaging, or any other eye pathology that in the opinion of the investigator would preclude enrollment) CAI Sub-study: Exclusion Criteria - Already being treated with CAIs - Previous documented failure to respond to CAI treatment Any drug-specific contraindication/precaution listed below (from www.micromedex.com): Topical Eye Drop Dorzolamide Hydrochloride Contraindications: • hypersensitivity to dorzolamide products, including sulfa allergies Precautions: - dorzolamide is a sulfonamide that is absorbed systemically, sulfonamide hypersensitivity reactions may occur - angle-closure glaucoma - concomitant use of oral carbonic-anhydrase inhibitors - conjunctivitis and lid reactions reported with chronic administration - moderate to severe renal (CrCl less than 30 mL/min) or hepatic insufficiency - ocular infection or inflammation - recent ocular surgery Topical Eye Drop Brinzolamide Contraindications: • hypersensitivity to any component of the product, including sulfa allergies Precautions: - concomitant use of oral carbonic anhydrase inhibitors is not recommended - contact lens use; remove contact lenses prior to administration, allow 15 minutes before reinsertion - hypersensitivity to sulfonamides; severe reaction may occur; discontinue if signs or symptoms appear - low corneal endothelial cell counts; increased risk of corneal edema - renal impairment, severe (CrCl less than 30 mL/min); use not recommended

Additional Information

Official title Clinical Evaluation of Patients With X-linked Retinoschisis (XLRS)
Principal investigator Mark A. Pennesi, MD, PhD
Description The objective of the study is to evaluate subjects with XLRS in a clinical setting and gather data on disease progression. The data from this study will enhance the understanding of the natural history of this rare disease and will facilitate appropriately powered safety studies in a future gene therapy trial in humans.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by Applied Genetic Technologies Corp.